Key Points
- Ra Capital Management, L.P. acquired 310,700 shares on March 27 at an average price of $23.67 (≈$7.35M), increasing its direct stake to 5,767,221 shares—a 5.69% position rise.
- Mineralys is a clinical-stage biopharma developing lorundrostat; shares opened at $26.97 with a market cap of about $2.22B, and the company reported Q results beating EPS estimates (loss of $0.40 vs. -$0.57 consensus).
- Wall Street shows cautious optimism with a consensus rating of "Moderate Buy" and a $49.14 target, while institutional investors own roughly 84.46% of the stock.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) Director Daphne Karydas sold 3,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $25.00, for a total transaction of $75,000.00. Following the completion of the transaction, the director directly owned 6,200 shares in the company, valued at $155,000. This trade represents a 32.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mineralys Therapeutics Price Performance
MLYS stock opened at $26.97 on Friday. Mineralys Therapeutics, Inc. has a 1 year low of $10.44 and a 1 year high of $47.65. The firm has a market capitalization of $2.22 billion, a PE ratio of -11.38 and a beta of 0.69. The business has a 50 day simple moving average of $28.00 and a 200-day simple moving average of $35.05.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. On average, equities research analysts expect that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on MLYS. Stifel Nicolaus boosted their price target on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a research report on Friday, December 19th. Jefferies Financial Group restated a "hold" rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a research report on Friday, March 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a report on Thursday, January 22nd. Wall Street Zen raised shares of Mineralys Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, March 15th. Finally, HC Wainwright set a $56.00 price target on shares of Mineralys Therapeutics and gave the stock a "buy" rating in a report on Tuesday, March 10th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Mineralys Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $49.14.
Read Our Latest Research Report on MLYS
Institutional Trading of Mineralys Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp boosted its stake in Mineralys Therapeutics by 144.4% during the fourth quarter. State Street Corp now owns 3,184,999 shares of the company's stock worth $115,584,000 after buying an additional 1,881,976 shares during the period. Farallon Capital Management LLC purchased a new stake in shares of Mineralys Therapeutics in the 3rd quarter valued at approximately $63,442,000. Price T Rowe Associates Inc. MD raised its stake in shares of Mineralys Therapeutics by 6,097.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,325,120 shares of the company's stock valued at $48,089,000 after acquiring an additional 1,303,737 shares during the period. Holocene Advisors LP acquired a new position in shares of Mineralys Therapeutics in the 3rd quarter worth approximately $45,708,000. Finally, Janus Henderson Group PLC lifted its holdings in shares of Mineralys Therapeutics by 6,012.8% in the 4th quarter. Janus Henderson Group PLC now owns 1,213,265 shares of the company's stock worth $44,005,000 after acquiring an additional 1,193,417 shares during the last quarter. 84.46% of the stock is currently owned by hedge funds and other institutional investors.
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
